| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 491.5 | 519.9 | 450.3 |
| Other income | 5.0 | 1.3 | 4.3 |
| Total income | 496.4 | 521.2 | 454.5 |
| Profit before exceptional items & tax | -33.3 | -22.5 | 4.4 |
| Exceptional items | -1.9 | -11.1 | 0.0 |
| Profit before tax | -34.9 | -32.3 | 4.0 |
| Net profit | -29.7 | -33.6 | -14.9 |
| Operating margin | -7.0% | -6.2% | 0.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +9.10% |
|---|---|
| Operating profit, year on year | -38400.00% |
| Operating profit, quarter on quarter | -60.90% |
BSE results filing, NSE: CAMLINFINE. Figures extracted from the filing.
Camlin Fine Sciences Ltd: key numbers
- Share price
- ₹74.15
- Market cap
- ₹1,424 Cr
- Revenue (annual)
- ₹1,723 Cr
- Net profit (annual)
- ₹27.63 Cr
- P/E (TTM)
- -187.7×Sector 34.1×
- Promoter holding
- 48.03%+0.00% QoQ
- FII holding
- 0.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Camlin Fine Sciences Ltd
All →Camlin Fine Sciences Earnings Call Transcript: Key Takeaways
EBITDA margin collapsed to about 0.5% from 3.4% as liquidity stress hit gross margin. A ₹250 Cr rights issue is pitched as the fix, and Q3 is described as a fight to stay afloat.
Camlin Fine Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs4,915mn (+9.2% YoY), but EBITDA margin fell to 0.45% and PAT loss was Rs281mn. Rights issue up to Rs2,500mn approved.
Camlin Fine Sciences Legal & Regulatory
SEBI issued an administrative warning to Camlin Fine Sciences over misclassified promoter-group shareholders in filings. No monetary penalty; compliance must improve to avoid enforcement.
Camlin Fine Sciences Board Meeting Date
Camlin Fine Sciences' board meets on 03 Nov 2026 to consider results and a proposed rights issue. Trading window closes until 05 Nov 2026.
Camlin Fine Sciences Share Pledge
Camlin Fine Sciences promoter-director Ashish Dandekar created pledges over 13.60 lakh shares worth ₹11.39 Cr. No change in shareholding; total pledged exposure rises for investors to monitor.
- Value
- ₹11.39 Cr
Camlin Fine Sciences Management Change
Mr. Pradip Kanakia ceased to be an Independent Director of Camlin Fine Sciences Ltd effective October 18, 2026, upon completion of his five-year term.